Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Re-do craniotomy for recurrent glioblastoma.

Literature DB >> 25768328

Re-do craniotomy for recurrent glioblastoma.

Ahmed A Morsy¹, Wai Hoe Ng.

Abstract

Entities: Disease

Keywords: glioblastoma multiforme; guidelines; progression; re-operation; recurrence

Mesh：

Year: 2015 PMID： 25768328 PMCID： PMC6093038 DOI： 10.2217/cns.15.4

Source DB: PubMed Journal: CNS Oncol ISSN： 2045-0907

× No keyword cloud information.

18 in total

1. Scale to predict survival after surgery for recurrent glioblastoma multiforme.

Authors: John K Park; Tiffany Hodges; Leopold Arko; Michael Shen; Donna Dello Iacono; Adrian McNabb; Nancy Olsen Bailey; Teri Nguyen Kreisl; Fabio M Iwamoto; Joohee Sul; Sungyoung Auh; Grace E Park; Howard A Fine; Peter McL Black
Journal: J Clin Oncol Date: 2010-07-19 Impact factor: 44.544

2. Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme.

Authors: J C Easaw; W P Mason; J Perry; N Laperrière; D D Eisenstat; R Del Maestro; K Bélanger; D Fulton; D Macdonald
Journal: Curr Oncol Date: 2011-06 Impact factor: 3.677

3. Impact of bevacizumab chemotherapy on craniotomy wound healing.

Authors: Aaron J Clark; Nicholas A Butowski; Susan M Chang; Michael D Prados; Jennifer Clarke; Mei-Yin C Polley; Michael E Sughrue; Michael W McDermott; Andrew T Parsa; Mitchel S Berger; Manish K Aghi
Journal: J Neurosurg Date: 2010-12-10 Impact factor: 5.115

4. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.

Authors: M Esteller; J Garcia-Foncillas; E Andion; S N Goodman; O F Hidalgo; V Vanaclocha; S B Baylin; J G Herman
Journal: N Engl J Med Date: 2000-11-09 Impact factor: 91.245

5. Trends in brain cancer incidence and survival in the United States: Surveillance, Epidemiology, and End Results Program, 1973 to 2001.

Authors: Sundeep Deorah; Charles F Lynch; Zita A Sibenaller; Timothy C Ryken
Journal: Neurosurg Focus Date: 2006-04-15 Impact factor: 4.047

6. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.

Authors: Orin Bloch; Seunggu J Han; Soonmee Cha; Matthew Z Sun; Manish K Aghi; Michael W McDermott; Mitchel S Berger; Andrew T Parsa
Journal: J Neurosurg Date: 2012-10-05 Impact factor: 5.115

7. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors: Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal: N Engl J Med Date: 2005-03-10 Impact factor: 91.245

Re-do craniotomy for recurrent glioblastoma.

1. Scale to predict survival after surgery for recurrent glioblastoma multiforme.

2. Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme.

3. Impact of bevacizumab chemotherapy on craniotomy wound healing.

4. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.

5. Trends in brain cancer incidence and survival in the United States: Surveillance, Epidemiology, and End Results Program, 1973 to 2001.

6. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.

7. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

8. BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors.

Review 9. Reoperation for recurrent high-grade glioma: a current perspective of the literature.

10. Independent association of extent of resection with survival in patients with malignant brain astrocytoma.

Review 1. Nasal Drug Delivery of Anticancer Drugs for the Treatment of Glioblastoma: Preclinical and Clinical Trials.